UCI Therapeutics develops multi-target fusion CAR-NK cell therapies that enhance the efficacy of natural killer (NK) cells against solid tumors by utilizing a cell-based fusion therapy approach. This technology addresses the limitations of existing immune cell therapies, such as high costs, manufacturing complexity, and severe side effects associated with current treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Existing CAR-T cell therapies for solid tumors face limitations including high manufacturing costs, patient-specific production requirements, challenges related to tumor heterogeneity, and severe side effects such as neurotoxicity and immune-related adverse events. These challenges restrict accessibility and efficacy, particularly in treating solid tumors.
Solution
UCI Therapeutics is developing allogeneic, multi-target fusion CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapies designed to enhance the efficacy and safety of adoptive NK cell immunotherapy in solid tumors. The company's CellTacT™ platform leverages genetically engineered NK cells to target solid tumors while overcoming limitations of traditional CAR-T therapies. By utilizing NK cells, UCI Therapeutics aims to reduce the risk of severe side effects, lower manufacturing costs through off-the-shelf allogeneic production, and address tumor heterogeneity through multi-antigen targeting. The platform is designed to improve the stability and delivery of biopharmaceuticals, offering a combination therapy effect with single substance administration.
Target Audience
The primary target audience includes patients with solid tumors who are not adequately served by existing therapies, as well as pharmaceutical companies seeking to expand their oncology portfolios with novel cell-based immunotherapies.
Features
- Allogeneic CAR-NK cell therapy for off-the-shelf availability
- CellTacT™ platform for cell-based targeted convergence therapy
- Multi-target approach to address tumor heterogeneity
- Genetically engineered NK cells to enhance tumor targeting and cytotoxicity
- Reduced risk of cytokine release syndrome and neurotoxicity compared to CAR-T therapies
- Combination therapy effect with single substance administration
- Proprietary technology to overcome limitations in stability and delivery of biopharmaceuticals
- In-house research and development at company-affiliated research facilities